• Consensus Rating: Buy
  • Consensus Price Target: GBX 150
  • Forecasted Upside: 44.93%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 103.50
▲ +0.5 (0.49%)

This chart shows the closing price for DXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Diaceutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXRX

Analyst Price Target is GBX 150
▲ +44.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Diaceutics in the last 3 months. The average price target is GBX 150, with a high forecast of GBX 150 and a low forecast of GBX 150. The average price target represents a 44.93% upside from the last price of GBX 103.50.

This chart shows the closing price for DXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Diaceutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/21/2024Canaccord Genuity GroupReiterated RatingBuyGBX 150
9/26/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
7/25/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
6/5/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
4/17/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
(Data available from 4/21/2019 forward)

News Sentiment Rating

1.61 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Diaceutics logo
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Read More

Today's Range

Now: GBX 103.50
Low: 103
High: 103.65

50 Day Range

MA: GBX 101.30
Low: 93.50
High: 107

52 Week Range

Now: GBX 103.50
Low: 79
High: 110

Volume

25,546 shs

Average Volume

61,214 shs

Market Capitalization

£87.64 million

P/E Ratio

10,500.00

Dividend Yield

N/A

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Diaceutics?

The following equities research analysts have issued reports on Diaceutics in the last year: Canaccord Genuity Group Inc..
View the latest analyst ratings for DXRX.

What is the current price target for Diaceutics?

2 Wall Street analysts have set twelve-month price targets for Diaceutics in the last year. Their average twelve-month price target is GBX 150, suggesting a possible upside of 44.9%. Canaccord Genuity Group Inc. has the highest price target set, predicting DXRX will reach GBX 150 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of GBX 150 for Diaceutics in the next year.
View the latest price targets for DXRX.

What is the current consensus analyst rating for Diaceutics?

Diaceutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXRX will outperform the market and that investors should add to their positions of Diaceutics.
View the latest ratings for DXRX.

What other companies compete with Diaceutics?